4DMedical Shares Up Double Digits as Volatile Trading Continues

4DMedical shares (ASX:4DX) jumped 13.31% today to close at A$3.83, extending a technical rebound from recent support levels as the respiratory imaging company continues to navigate extreme volatility despite a string of major commercial and regulatory wins.

The 4DMedical share price continues to bounce off support around A$3.20 that has held through recent selling pressure, yet despite today’s double-digit gain, 4DX remains 40% lower over the past month, following a dramatic pullback from early April highs when the stock had gained more than 50% year-to-date. Calling the shares volatile this year would be an understatement, with recent whipsaw action proving a little testy for even the most battle hardened.

Recent Fundamentals

4DMedical develops and commercialises respiratory imaging technology, with its flagship CT:VQ product representing the first and only CT-based ventilation-perfusion imaging technology cleared by the US Food and Drug Administration. The technology provides detailed lung function analysis using standard CT scanners, positioning it as a potential alternative to traditional nuclear medicine VQ scans.

The company’s most recent full-year results for FY2024, released on 30 August 2024, showed operating revenue of A$3.8 million, up 422% year-on-year but still modest in absolute terms. Product revenue totalled A$1.1 million from 4DMedical’s core business and A$2.7 million from recently acquired Imbio. The company also benefited from significant grant and research support, including funding from the Medical Research Future Fund.

Recent months have delivered a cascade of commercial and regulatory milestones that underpin the bullish long-term thesis, even as markets grapple with the gap between current financials and the company’s multi-billion dollar market capitalisation at recent peaks.

Approximately three months ago, 4DMedical completed a A$150 million institutional placement to fund its US commercial rollout, with strong demand from global institutional investors viewed as a vote of confidence in the business model. CEO Andreas Fouras and CFO exercised performance options early during this period, lifting their combined stake to approximately 12.4% of the company.

Strategic Wins

The volatility has unfolded against a backdrop of genuinely positive business developments. 4DMedical secured FDA 510(k) clearance for CT:VQ in the United States and obtained regulatory approvals in Canada and the United Kingdom, opening pathways into major developed markets. Critically, the company achieved Medicare reimbursement approval from the Centers for Medicare & Medicaid Services, establishing a clear revenue model for US hospital adoption with per-scan reimbursement in the hundreds of dollars.

On the commercial front, Mayo Clinic’s adoption of CT:VQ technology represented a significant validation, with the prestigious health system serving as a powerful reference site for broader hospital network penetration. The company has also established a distribution partnership with Philips, leveraging the imaging giant’s substantial salesforce to accelerate market penetration alongside Philips’ CT hardware and software solutions.

Most recently, 4DMedical announced a one-year engagement with GlaxoSmithKline to provide quantitative lung imaging analytics for pulmonary drug development and clinical research, effective from 1 May 2026. The agreement, facilitated through Flywheel Exchange, expands 4DMedical’s addressable market beyond hospital clinical use into pharmaceutical research and development, clinical trials, and potentially companion diagnostics.

Valuation Debate

The central tension driving 4DMedical’s wild price swings centres on valuation. Bulls point to a massive total addressable market spanning hundreds of thousands to over a million potential scans annually in the US alone, with high software-like margins and leverage to existing CT infrastructure. They emphasise that regulatory clearances, reimbursement codes, blue-chip reference sites, and a large distribution partner create a clear pathway from current single-digit millions in revenue to hundreds of millions at scale.

Bears counter that the company remains deeply speculative, with a market capitalisation that reached into the billions during recent peaks despite operating product revenue of just over A$1 million in the last reported period. They highlight execution risk in hospital adoption, workflow integration challenges, and the reality that meaningful revenue from recent contract wins may not materialise until mid-2026 or beyond. The stock’s history of extreme volatility, including an approximate 90% decline from 2020 to mid-2025 before its recent ten-fold rebound, underscores the risk profile.

From a technical perspective, today’s bounce appears to reflect a classic oversold rebound after a steep correction. The A$3.20 to A$3.30 zone has provided support as selling pressure from profit-takers waned and dip-buyers stepped in. Whether this level holds will likely depend on the next round of quarterly results and evidence of accelerating scan volumes and hospital adoption.

The company’s strong cash position following the A$150 million raise provides runway to execute its commercial strategy without immediate dilution risk, but markets will be watching for concrete evidence that regulatory wins and partnership announcements are translating into meaningful revenue growth.